Overexpression and amplification of human epidermal growth factor receptor 2 (HER2) are detected in approximately 15%–20% of all breast cancer cases and have historically been considered to be prognostic for poorer survival outcomes [2, 3]. Here, ERBB2 is linked to breast carcinoma.